Synaptogenix (Synaptogenix) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Synaptogenix's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Synaptogenix's average Total Assets over the quarter that ended in Mar. 2024 was $30.26 Mil. Therefore, Synaptogenix's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Synaptogenix Gross-Profit-to-Asset % Historical Data

The historical data trend for Synaptogenix's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix Gross-Profit-to-Asset % Chart

Synaptogenix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Synaptogenix Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Synaptogenix's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Synaptogenix's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synaptogenix's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synaptogenix's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Synaptogenix's Gross-Profit-to-Asset % falls into.

Synaptogenix Gross-Profit-to-Asset % Calculation

Synaptogenix's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (38.608	+	31.114)	/ 2 )
	=	0	/	34.861
	=	0.00 %

Synaptogenix's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (31.114	+	29.399)	/ 2 )
	=	0	/	30.2565
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Synaptogenix Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Synaptogenix's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synaptogenix (Synaptogenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.synaptogen.com

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Executives

Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer	director	C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon	director, officer: Chief Scientific Officer	C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman	director, officer: Chief Executive Officer	18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry	director	C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010